# reload+after+2024-01-21 07:43:12.493918
address1§Technologiepark
address2§Im Neuenheimer Feld 582
city§Heidelberg
zip§69120
country§Germany
phone§49 6221 6743 60
fax§49 6221 6743 649
website§https://www.affimed.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
fullTimeEmployees§219
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Adi  Hoess M.D., Ph.D.', 'age': 62, 'title': 'CEO, MD & Member of Management Board', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 837038, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Harry  Welten M.B.A.', 'age': 58, 'title': 'Interim Chief Financial Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 53684, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Wolfgang  Fischer', 'age': 59, 'title': 'MD, COO & Member of Management Board', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 652978, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Denise  Mueller', 'age': 53, 'title': 'Chief Business Officer & Member of Management Board', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 635448, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Andreas  Harstrick M.D.', 'age': 62, 'title': 'Chief Medical Officer & Member of Management Board', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 541226, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Arndt Justus Georg Schottelius M.D., Ph.D.', 'age': 57, 'title': 'Chief Scientific Officer & Member of Management Board', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 656264, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Prof. Melvyn  Little', 'title': 'Founder & Consultant', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael  Wolf', 'age': 56, 'title': 'Head of Finance & Administration', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alexander  Fudukidis', 'title': 'Head of Investor Relations & Director of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mary Beth Sandin', 'title': 'Vice President of Marketing & Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§1
boardRisk§4
compensationRisk§10
shareHolderRightsRisk§3
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.058
priceToSalesTrailing12Months§4.3767734
currency§USD
dateShortInterest§1702598400
forwardEps§-0.68
exchange§NCM
quoteType§EQUITY
shortName§Affimed N.V.
longName§Affimed N.V.
firstTradeDateEpochUtc§1410528600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§a8ac0d1a-dfe3-38a8-9a5f-268608bb683d
gmtOffSetMilliseconds§-18000000
targetHighPrice§7.02
targetLowPrice§1.01
targetMeanPrice§4.22
targetMedianPrice§5.02
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§3.459
grossMargins§0.47804
ebitdaMargins§0.0
trailingPegRatio§None
